Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW.

J Immunol. 2008 May 15;180(10):7028-38.

2.

Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.

James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW.

J Immunol. 2010 Apr 15;184(8):4284-94. doi: 10.4049/jimmunol.0903701. Epub 2010 Mar 10. Erratum in: J Immunol. 2010 Jul 15;185(2):1340.

3.

Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.

Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M.

J Immunol. 2015 Feb 1;194(3):911-20. doi: 10.4049/jimmunol.1402346. Epub 2014 Dec 17.

4.

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.

Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B.

J Immunol. 2008 Jul 15;181(2):1063-70.

5.

Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.

Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M.

Clin Cancer Res. 2002 Dec;8(12):3885-92.

7.

Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.

Kawano K, Efferson CL, Peoples GE, Carter D, Tsuda N, Murray JL, Ioannides CG.

Cancer Res. 2005 Apr 1;65(7):2930-7.

8.

Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.

James SE, Orgun NN, Tedder TF, Shlomchik MJ, Jensen MC, Lin Y, Greenberg PD, Press OW.

Blood. 2009 Dec 24;114(27):5454-63. doi: 10.1182/blood-2009-08-232967. Epub 2009 Oct 30.

9.

Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.

Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD.

J Immunol. 1999 Feb 15;162(4):2227-34.

11.

CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Altvater B, Pscherer S, Landmeier S, Niggemeier V, Juergens H, Vormoor J, Rossig C.

Clin Exp Immunol. 2006 Jun;144(3):447-57.

12.

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

Weng J, Rawal S, Chu F, Park HJ, Sharma R, Delgado DA, Fayad L, Fanale M, Romaguera J, Luong A, Kwak LW, Neelapu SS.

Blood. 2012 Aug 23;120(8):1613-23. doi: 10.1182/blood-2011-09-382838. Epub 2012 May 29.

13.

Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis.

Ren-Heidenreich L, Mordini R, Hayman GT, Siebenlist R, LeFever A.

Cancer Immunol Immunother. 2002 Oct;51(8):417-23. Epub 2002 Jul 23.

PMID:
12202902
15.

Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.

Dutoit V, Rubio-Godoy V, Doucey MA, Batard P, Liénard D, Rimoldi D, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D.

J Immunol. 2002 Feb 1;168(3):1167-71.

16.

High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA.

J Immunol. 2003 Sep 15;171(6):3287-95.

17.

Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex.

Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JL, O'Brian CA, Ioannides CG.

J Immunol. 2002 Oct 1;169(7):3545-54.

18.

Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.

Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, Hosen N, Nishida S, Lin YH, Tachino S, Akatsuka Y, Kuzushima K, Oji Y, Kumanogoh A, Sugiyama H.

Anticancer Res. 2012 Dec;32(12):5201-9.

PMID:
23225417
19.

Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.

Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.

Clin Cancer Res. 2005 May 1;11(9):3446-54.

20.

Superimposed epitopes restricted by the same HLA molecule drive distinct HIV-specific CD8+ T cell repertoires.

Sun X, Fujiwara M, Shi Y, Kuse N, Gatanaga H, Appay V, Gao GF, Oka S, Takiguchi M.

J Immunol. 2014 Jul 1;193(1):77-84. doi: 10.4049/jimmunol.1400375. Epub 2014 Jun 4.

Supplemental Content

Support Center